About us

HCD was created out of an alliance with University of Chester, charities and health service sectors in reponse to the ever-growing demand for economic analysis within healthcare and specifically the need for health economics and business intelligence within the public and third sectors.

Through these partnerships, HCD provides a unique insight and perspective, focusing our analyses on what matters to patients as well as decision-makers, all undertaken with academic rigour, independence and credibility.

Continue Reading
Scroll for more

Our Process

We have created core partnerships with University of Chester and leading patient charities that underpin our approach.

Higher education

Academia has a leading role to play in providing an independent, credible evidence-base as well as evaluating current and new ways of delivering healthcare.


Our partnerships with patient charities ensure that any analyses we undertake reflect the day-to-day realities of living with a particular condition.


We apply primary or secondary real world data sources depending on research needs and questions. From ethically reviewed burden of illness studies and bespoke service primary data, to secondary sourced disease registries and episode statistics.

Scroll for more

Latest News

Check out what is happening at HCD Economics

July 2020

Rare revolution magazine publishes CEO interview with Jamie O’Hara

Rare Revolution Magazine is published quarterly and reaches over 4000 readers in the rare disease community. The digital magazine is dedicated to giving rare disease a voice. The Rare Revolution Magazine features ‘The People of Rare’, these are interviews with CEOs of professional organisations, and the Editors describe the interviewees as ‘the beating hearts who are making their mark on the work of rare disease’.
Continue Reading
June 2020

Health State Utilities for Beta-Thalassaemia – new study launches new HCD research franchise

HCD Economics is setting research priorities in the field of rare disease and blood related disorders. Beta-Thalassaemia is the latest disease to be incorporated into the HCD research portfolio. HCD Economics is focused on understanding the beta-thalassemia patient and with that understanding, undertake socio-economic research to generate evidence to support patient advocacy.
Continue Reading
Scroll for more

Get in touch

...and one of our experts will get back to you ASAP.

Please be advised that we will not use your details for marketing purposes
Scroll for more